
sep pm et
summari compani develop provid research product servic analysi
genet variat function
price-to-earnings oper ep
risk assess reflect high depend
rapid technolog advanc maintain growth
expect highli competit marketplac
rel new industri oper
breadth client depend govern
fund risk somewhat balanc
domin market share sticki custom dna
ep estim base cfra oper earn histor
earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
jun-q sale grew yoy led consum
grew yoy fastest
growth rate consum sinc
attribut robust demand latest
gener novaseq system introduc
yoy continu robust consum demand
increas shipment novaseq system
jun-q also saw increas ebita
yoy driven sale growth basi
point improv ebita margin
major margin gain came greater
sale mix consum less
instrument instrument made
sale
notabl higher
margin consum also
instrument sale histor
cyclic compon sale
experienc neg growth extend
period
instrument growth tend follow product
addit organ growth
quarter encourag
acquisit edico genom lead provid
sequenc data analysi solut think
combin genet data creation analysi
tool aid long-term growth
think maintain lead
accordingli deserv premium valuat
peer becom cautiou howev
forward price-to-earnings multipl use
estim appear expens us even
consid robust growth outlook
improv margin note stock
histori rapid gain new instrument
uptak cycl hiseq
hiseq follow sluggish
period growth expect cool weak
period tend follow run-up
forward price-to-earnings level
risk view upsid sustain
higher-than-norm valuat could occur
better-than-expect sale next
gener system downsid risk
signific declin govern fund
target price ep estim
materi
forward price-to-earnings averag roughli
premium due increas shift toward
consum sale acceler
histor less cyclic
instrument sale
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
oper
corpor overview develop research tool large-scal analysi genet variat
function account physic differ among human eye color height
genet variat also import medic consequ includ predisposit diseas
differenti respons drug tool assist research autom billion test necessari
collect raw genet data imbed dna sequenc contain everi live cell
scientist use data investig dna sequenc dictat biolog event molecular
scale develop inform medic valuabl applic field studi known
genom rapidli expand given potenti custom diagnos treatment
improv drug therapi cure diseas
corpor strategi import aspect ilmn busi understand relationship
dna sequenc machin instrument consum instrument perman fixtur
laboratori larg up-front cost ilmn power dna sequenc machin novaseq
releas januari cost roughli per unit convers consum lower-cost
prepar kit scientist arrang test sampl feed machin run dna
sequenc test product relationship somewhat analog razor razor blade model
lab typic purchas small number instrument continu order larg volum
consum life machin run thousand sequenc test way singl
instrument sale lead durabl long-term sale consum
last decad ilmn annual sale growth follow cyclic trend relat new instrument
launch five-quart stretch year-over-year sale growth averag coincid launch
hiseq sequenc machin hiseq launch produc five
quarter growth averag new instrument ramp growth tend slower
expans ilmn instal base instrument field new product launch actual
reduc cyclic howev higher baselin recur consum servic demand
establish ilmn contribut sale instrument fallen
view favor
januari introduc novaseq system line think could reduc cost
sequenc within year note year-over-year instrument sale
fell posit growth neg june quarter howev event typic occur near
peak total sale growth expect ilmn cyclic sale growth slow lower novaseq
product cycl howev due larger sale mix consum versu previou cycl
market profil signific custom concentr tool servic use
research govern univers lab well commerci pharmaceut biotechnolog
agrigenom diagnost lab around world custom increas util
ilmn tool servic genom field rapidli develop first half geograph
composit year-over-year growth respect ilmn total sale unit state total
sequenc technolog continu advanc cost sequenc singl genom entir set
dna data contain cell continu fall accord nation institut cost
sequenc genom took sever week versu around sever
hour reduc time cost allow increas number entrant appli
genom market accord cb insight juli global fund genom startup
alreadi surpass record set pace doubl full-year
expect particip increasingli util sequenc tool servic effort develop
clinic commerci genom applic
competit landscap competit landscap intens sever larger
diversifi publicly-trad compani industri well numer emerg privat compani
publicly-trad compani includ thermo fisher scientif acquir main competitor life
technolog februari agil amersham bioscienc subsidiari ge
undisput leader next gener sequenc system howev market share
estim compani sizabl instal base system like ilmn hold
competit advantag emerg compani view instal system drive
persist sale consum product util consist invest innov
also transit one system anoth costli time-consum given requir train
new system level integr sequenc instrument laboratori work flow
financi trend sale growth driven robust uptak ilmn new sequenc system
turn increas instal instrument base turn lead higher consum sale sale
increas year end june compound annual growth rate
compound-annual-growth-rate perid earn tax amort increas
compound-annual-growth-rate adjust ep increas compound-annual-growth-rate illumina
conserv capit net debt neg ebita/net interest june
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month think among
fastest-grow sub-industri within
health care sector see solid fund
privat public sourc help drive
billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain
initi support alzheim diseas
overal see mid-singl high-singl digit
sale growth emerg market
china remain robust growth region
grow rate mid-teen help fuel
overal industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
end-market howev note mani life
scienc compani activ pursu
initi commerci non-academ
govern revenu base
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
servic rose vs rise
 composit index year date
juli life scienc tool
servic rose vs rise
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
sell custom share rose significantli follow
announc deal two largest firm genet sequenc
space rais possibl partnership rais target
peer ep estim /jeffrey loo cfa
et cfra rais opinion share buy
hold rais target
peer forward ep estim faster growth
ep vs ahead estim rais
ep estim sale rose
best growth rate sinc sale rose driven strong adopt
novaseq platform ship novaseq sinc launch
januari includ see continu robust growth
see client base expand includ previou benchtop custom /jeffrey
et cfra keep hold opinion share inc
rais target price above-p
forward ep estim within rang
ep vs ahead estim sale
rose driven strong demand novaseq sequenc consum
microarray receiv order novaseq sinc launch
januari order come hiseq replac cycl
look continu robust order flow hiseq replac cycl
begin interest commerci custom grow /jeffrey loo cfa
et cfra keep hold opinion share inc
rais target peer
next ep estim keep ep estim
rais ep vs line
estim sale rose solid growth consum
servic partial off-set declin instrument anticip
novaseq launch expect oper margin fell
headcount increas invest grail helix believ demand
novaseq next gener sequenc strong order /jeffrey
analyst research note compani news
maintain target price
ep estim materi averag roughli
premium due acceler growth expect uptak next
gener sequenc system maintain ep estim
sale yoy sharp acceler growth rate
respect encourag perform
particularli strong demand seen newest novaseq system
replac last gener system sale strength driven share
year-to-d price-to-earnings ntm earn forecast level
last seen summer previou gener upgrad cycl
peak price eclips fall even sale growth remain
robust period think busi outlook remain
strong cautiou valuat given ever-high expect
growth /colin scarola
et cfra keep buy opinion share inc
rais target price peer
forward ep estim within five year rang
ep vs ahead estim
rais ep estim ep estim
sale rose well forecast sale growth
broad-bas product growth across consum servic well
geograph growth consum servic account sale
compar year ago aid gross margin improv basi
point howev instrument sale fell compar year ago
sequenc instrument grew last quarter encourag
robust growth genom inform believ demand expand
research market within clinic consum market
see well posit captur signific portion market
et cfra reiter buy opinion share inc
rais target price
peer ep estim within five
year rang rais ep estim ep
vs ahead estim sale rose well
growth forecast robust demand consum particularli
novaseq consum grew sequenti year ago
sequenc instrument rose strong novaseq sale offset
expect declin hiseq instrument expect robust consum sale
throughout year ilmn client base expand approxim
novaseq instrument order came new custom
straight-from-benchtop util lower throughput
instrument past also see continu demand hiseq
custom transit novaseq also see benefit
increas nih budget /jeffrey loo cfa
et cfra reiter buy opinion share inc
rais target peer
ep estim set ep
vs ahead view sale rose robust
rise sequenc consum growth instrument novaseq
shipment high ship sinc launch
januari new client look anoth robust year
novaseq hiseqx client transit platform also
think use sequenc move rapidli commerci applic
et cfra reiter buy opinion share
thermo fisher scientif announc
deal enabl sell ion ampliseq technolog research
util next-gener sequenc platform sell
product name ampliseq continu
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
